Lea County, New Mexico, is now reporting an outbreak of measles, according to the New Mexico Department of Health.

We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...

It’s really important to continue to focus on ensuring that those who devote their lives to protecting the public and communities continue to receive coverage through the special claims unit,” said ...

GEMSTONE-303 is the first trial demonstrating a statistically significant survival benefit for addition of an anti-PD-L1 antibody to standard chemotherapy for advanced gastric and gastroesophageal ...

PE-related deaths among patients with cancer increased 44.3% between 2011 and 2020, rising by about 2.9% each year during the study period ( P <.001). On average, the age-adjusted mortality rate (AAMR ...

The FDA has granted priority review to the new drug application for zongertinib to treat adults with unresectable or metastatic, HER2-mutant NSCLC who have received prior systemic therapy.

Inpatient immune checkpoint inhibitor treatment produces poor outcomes across cancer types, according to the largest study of its kind.

Researchers found that cancer incidence is on the decline for Black patients and rising for White patients, but mortality is on the decline for both groups.

A phytochemical-rich food supplement can slow PSA progression in patients with prostate cancer, and adding a probiotic can enhance this effect.

Fixed-duration acalabrutinib and venetoclax, with or without obinutuzumab, may improve outcomes over chemoimmunotherapy in patients with previously untreated CLL.

The AlloHeme test can be used to predict relapse after allogeneic HCT in patients with AML or MDS, data suggest.

Further assessment is needed to understand if these treatment recommendations were eventually adopted and if adoption leads to better outcomes,” researchers wrote.